Galapagos NV (F:GXEA) — Market Cap & Net Worth
Market Cap & Net Worth: Galapagos NV (GXEA)
Galapagos NV (F:GXEA) has a market capitalization of $1.60 Billion (€1.37 Billion) as of August 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #6866 globally and #997 in its home market, demonstrating a -4.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Galapagos NV's stock price €24.00 by its total outstanding shares 65897071 (65.90 Million). See GXEA capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
Galapagos NV Market Cap History: 2015 to 2026
Galapagos NV's market capitalization history from 2015 to 2026. Data shows change from $4.36 Billion to $1.85 Billion (-5.13% CAGR).
Galapagos NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Galapagos NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.93x
Galapagos NV's market cap is 1.93 times its annual revenue
Latest Price to Earnings (P/E) Ratio
6.67x
Galapagos NV's market cap is 6.67 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.68 Billion | $129.52 Million | $54.01 Million | 36.14x | 86.67x |
| 2017 | $6.07 Billion | $127.09 Million | -$115.70 Million | 47.76x | N/A |
| 2018 | $5.89 Billion | $288.84 Million | -$29.26 Million | 20.40x | N/A |
| 2019 | $14.33 Billion | $844.99 Million | $149.84 Million | 16.96x | 95.63x |
| 2020 | $5.97 Billion | $478.05 Million | -$305.44 Million | 12.49x | N/A |
| 2021 | $3.54 Billion | $484.85 Million | -$103.23 Million | 7.31x | N/A |
| 2022 | $3.07 Billion | $505.28 Million | -$217.99 Million | 6.07x | N/A |
| 2023 | $2.70 Billion | $239.72 Million | $211.70 Million | 11.25x | 12.74x |
| 2024 | $1.99 Billion | $275.65 Million | $74.08 Million | 7.21x | 26.83x |
| 2025 | $2.14 Billion | $1.11 Billion | $320.88 Million | 1.93x | 6.67x |
Competitor Companies of GXEA by Market Capitalization
Companies near Galapagos NV in the global market cap rankings as of August 3, 2026.
Key companies related to Galapagos NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Galapagos NV Historical Marketcap From 2015 to 2026
Between 2015 and today, Galapagos NV's market cap moved from $4.36 Billion to $ 1.85 Billion, with a yearly change of -5.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.85 Billion | -13.67% |
| 2025 | €2.14 Billion | +7.75% |
| 2024 | €1.99 Billion | -26.29% |
| 2023 | €2.70 Billion | -12.06% |
| 2022 | €3.07 Billion | -13.48% |
| 2021 | €3.54 Billion | -40.65% |
| 2020 | €5.97 Billion | -58.33% |
| 2019 | €14.33 Billion | +143.14% |
| 2018 | €5.89 Billion | -2.90% |
| 2017 | €6.07 Billion | +29.66% |
| 2016 | €4.68 Billion | +7.37% |
| 2015 | €4.36 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of Galapagos NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.60 Billion USD |
| MoneyControl | $1.60 Billion USD |
| MarketWatch | $1.60 Billion USD |
| marketcap.company | $1.60 Billion USD |
| Reuters | $1.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Galapagos NV
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in… Read more